Cargando…
L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle
Sarcopenia is a common complication of cirrhosis with a negative impact on posttransplant outcome, health-related quality of life (HRQOL), and patient survival. Studies in experimental animals and in patients demonstrate that ammonia is directly implicated in the pathogenesis of sarcopenia in cirrho...
Autor principal: | Butterworth, Roger F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512019/ https://www.ncbi.nlm.nih.gov/pubmed/31183339 http://dx.doi.org/10.1155/2019/8182195 |
Ejemplares similares
-
l-Ornithine l-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses
por: Butterworth, Roger F., et al.
Publicado: (2019) -
Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis
por: Butterworth, Roger F.
Publicado: (2019) -
l-Ornithine l-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease
por: Canbay, Ali, et al.
Publicado: (2019) -
Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy
por: Kircheis, Gerald, et al.
Publicado: (2019) -
Effect of l-ornithine l-aspartate against thioacetamide-induced hepatic damage in rats
por: Najmi, Abul K., et al.
Publicado: (2010)